Mylan
Canonsburg, PA 15317
Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance
MORGANTOWN, W.Va., Oct. 25, 2019 /PRNewswire/ -- Mylan Pharmaceuticals Inc. is conducting a voluntary nationwide recall of one lot (see table below) of Alprazolam Tablets, USP C-IV 0.5 mg, to the consumer/user level. This lot is being recalled due to the potential presence of foreign substance. Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk...
Read More »
New Buprenorphine and Naloxone Sublingual Film Indicated for The Treatment of Opioid Dependence
FDA approved Buprenorphine and Naloxone Sublingual film are available in 8 mg/2 mg and 12 mg/3 mg. The prescription is limited to healthcare providers who meet certain qualifying requirements. Should be used as part of a complete treatment plan to include counseling and psychosocial support.
Read More »Mylan and Pfizer Receive Clearance from The U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn
Pfizer Announces Record Date for the Proposed Transaction Hertfordshire, England and Pittsburgh and New York, Oct. 30, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the FTC ) accepted a proposed consent order, which concludes the FTC's review of the proposed combination of Mylan and Pfizer's Upjohn Business....
Read More »
Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance
MORGANTOWN, W.Va., Oct. 25, 2019 /PRNewswire/ -- Mylan Pharmaceuticals Inc. is conducting a voluntary nationwide recall of one lot (see table below) of Alprazolam Tablets, USP C-IV 0.5 mg, to the consumer/user level. This lot is being recalled due to the potential presence of foreign substance. Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk...
Read More »
New Buprenorphine and Naloxone Sublingual Film Indicated for The Treatment of Opioid Dependence
FDA approved Buprenorphine and Naloxone Sublingual film are available in 8 mg/2 mg and 12 mg/3 mg. The prescription is limited to healthcare providers who meet certain qualifying requirements. Should be used as part of a complete treatment plan to include counseling and psychosocial support.
Read More »Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
PITTSBURGH, March 22, 2011 - Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary UDL Laboratories, part of the Mylan Institutional business, has entered a license agreement with Humeca, a leading plastic surgery and burn treatment products company, for the exclusive U.S. distribution rights of Humeca products. Humeca, which is based in the Netherlands, has a portfolio that includes...
Read More »Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
Company also launches new Mylan Institutional business PITTSBURGH, Sept. 7 - Mylan Inc. (NASDAQ:MYL) today announced it has completed the acquisition of Bioniche Pharma Holdings Limited sooner than anticipated. Bioniche Pharma, an injectable pharmaceutical company, is providing Mylan with immediate entry into the North American injectables market and a platform for the commercialization of future...
Read More »